Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results Director departure
|
Juno Therapeutics, Inc. (JUNO)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
02/13/2019 |
SC 13G/A
| Capital International Investors reports a 0% stake in Juno Therapeutics Inc. |
04/16/2018 |
CT ORDER
| Form CT ORDER - Confidential treatment order: |
03/16/2018 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
03/09/2018 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
03/09/2018 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
03/07/2018 |
4
| Wilderotter Mary Agnes (Director) has filed a Form 4 on Juno Therapeutics, Inc.
Txns:
| Disposed/sold 75,000 options to buy
@ $8.72, valued at
$654k
Disposed/sold 12,000 options to buy
@ $60, valued at
$720k
Disposed/sold 12,000 options to buy
@ $42.4, valued at
$508.8k
Disposed/sold 12,000 options to buy
@ $23.29, valued at
$279.5k
|
|
03/07/2018 |
4
| PIEN HOWARD H (Director) has filed a Form 4 on Juno Therapeutics, Inc.
Txns:
| Gifted 12,251 shares
@ $0 Gifted 1,162 shares
@ $0 Unknown transaction of 111,587 shares
@ $87, valued at
$9.7M
Disposed/sold 5,050 shares
@ $87, valued at
$439.4k
Disposed/sold 12,000 options to buy
@ $60, valued at
$720k
Disposed/sold 12,000 options to buy
@ $42.4, valued at
$508.8k
Disposed/sold 12,000 options to buy
@ $23.29, valued at
$279.5k
|
|
03/07/2018 |
4
| NELSEN ROBERT (Director) has filed a Form 4 on Juno Therapeutics, Inc.
Txns:
| Unknown transaction of 50,824 shares
@ $87, valued at
$4.4M
Disposed/sold 3,234 shares
@ $87, valued at
$281.4k
Unknown transaction of 10,552,390 shares
@ $87, valued at
$918.1M
Disposed/sold 12,000 options to buy
@ $60, valued at
$720k
Disposed/sold 12,000 options to buy
@ $42.4, valued at
$508.8k
Disposed/sold 12,000 options to buy
@ $23.29, valued at
$279.5k
|
|
03/07/2018 |
4
| LEE ANN L. (EVP, Technical Operations) has filed a Form 4 on Juno Therapeutics, Inc.
Txns:
| Disposed/sold 35,004 shares
@ $0 Disposed/sold 40,788 shares
@ $0 Disposed/sold 35,000 shares
@ $0 Disposed/sold 152,900 options to buy
@ $62.85, valued at
$9.6M
|
|
03/07/2018 |
4
| Klausner Richard (Director) has filed a Form 4 on Juno Therapeutics, Inc.
Txns:
| Gifted 23,250 shares
@ $0 Unknown transaction of 705,525 shares
@ $87, valued at
$61.4M
Disposed/sold 12,000 options to buy
@ $60, valued at
$720k
Disposed/sold 12,000 options to buy
@ $42.4, valued at
$508.8k
Disposed/sold 12,000 options to buy
@ $23.29, valued at
$279.5k
|
|
03/07/2018 |
4
| Harr Steve (CFO & Head, Corp. Development) has filed a Form 4 on Juno Therapeutics, Inc.
Txns:
| Unknown transaction of 492,355 shares
@ $87, valued at
$42.8M
Disposed/sold 50,010 shares
@ $87, valued at
$4.4M
Disposed/sold 20,580 shares
@ $0 Disposed/sold 29,135 shares
@ $0 Disposed/sold 11,544 shares
@ $0 Disposed/sold 35,893 shares
@ $0 Disposed/sold 98,750 options to buy
@ $8.72, valued at
$861.1k
Disposed/sold 85,000 options to buy
@ $48.06, valued at
$4.1M
Disposed/sold 155,000 options to buy
@ $24.5, valued at
$3.8M
Disposed/sold 127,841 options to buy
@ $20.76, valued at
$2.7M
|
|
03/07/2018 |
4
| FLATLEY JAY T (Director) has filed a Form 4 on Juno Therapeutics, Inc.
Txns:
| Unknown transaction of 31,500 shares
@ $87, valued at
$2.7M
Disposed/sold 18,000 options to buy
@ $24.07, valued at
$433.3k
Disposed/sold 12,000 options to buy
@ $23.29, valued at
$279.5k
|
|
03/07/2018 |
4
| EVNIN ANTHONY B (Director) has filed a Form 4 on Juno Therapeutics, Inc.
Txns:
| Gifted 25,000 shares
@ $0 Gifted 34,842 shares
@ $0 Disposed/sold 12,000 options to buy
@ $60, valued at
$720k
Disposed/sold 12,000 options to buy
@ $42.4, valued at
$508.8k
Disposed/sold 12,000 options to buy
@ $23.29, valued at
$279.5k
|
|
03/07/2018 |
4
| Daniel Thomas O (Director) has filed a Form 4 on Juno Therapeutics, Inc.
Txns:
| Disposed/sold 12,000 options to buy
@ $23.29, valued at
$279.5k
|
|
03/07/2018 |
4
| Cassidy Bernard J (General Counsel & Secretary) has filed a Form 4 on Juno Therapeutics, Inc.
Txns:
| Unknown transaction of 5,558 shares
@ $87, valued at
$483.5k
Disposed/sold 18,293 shares
@ $0 Disposed/sold 25,639 shares
@ $0 Disposed/sold 35,893 shares
@ $0 Unknown transaction of 26,869 shares
@ $87, valued at
$2.3M
Disposed/sold 125,000 options to buy
@ $6.36, valued at
$795k
Disposed/sold 37,500 options to buy
@ $8.72, valued at
$327k
Disposed/sold 50,500 options to buy
@ $48.06, valued at
$2.4M
Disposed/sold 75,000 options to buy
@ $24.5, valued at
$1.8M
Disposed/sold 113,636 options to buy
@ $20.76, valued at
$2.4M
|
|
03/07/2018 |
4
| Bishop Hans Edgar (CEO & President) has filed a Form 4 on Juno Therapeutics, Inc.
Txns:
| Unknown transaction of 2,263,948 shares
@ $87, valued at
$197M
Disposed/sold 48,829 shares
@ $87, valued at
$4.2M
Disposed/sold 33,133 shares
@ $0 Disposed/sold 66,426 shares
@ $0 Disposed/sold 35,893 shares
@ $0 Disposed/sold 451,756 options to buy
@ $6.36, valued at
$2.9M
Disposed/sold 140,000 options to buy
@ $48.06, valued at
$6.7M
Disposed/sold 200,000 options to buy
@ $24.5, valued at
$4.9M
Disposed/sold 205,823 options to buy
@ $20.76, valued at
$4.3M
|
|
03/07/2018 |
4
| Barron Hal (Director) has filed a Form 4 on Juno Therapeutics, Inc.
Txns:
| Unknown transaction of 100,000 shares
@ $87, valued at
$8.7M
Disposed/sold 3,780 shares
@ $87, valued at
$328.9k
Disposed/sold 75,000 options to buy
@ $6.36, valued at
$477k
Disposed/sold 12,000 options to buy
@ $60, valued at
$720k
Disposed/sold 12,000 options to buy
@ $42.4, valued at
$508.8k
Disposed/sold 12,000 options to buy
@ $23.29, valued at
$279.5k
|
|
03/07/2018 |
4
| Azelby Robert (EVP & Chief Commercial Officer) has filed a Form 4 on Juno Therapeutics, Inc.
Txns:
| Disposed/sold 7,500 shares
@ $0 Disposed/sold 20,580 shares
@ $0 Disposed/sold 25,639 shares
@ $0 Disposed/sold 35,893 shares
@ $0 Disposed/sold 93,294 options to buy
@ $51.76, valued at
$4.8M
Disposed/sold 30,002 options to buy
@ $25.29, valued at
$758.8k
Disposed/sold 98,545 options to buy
@ $20.76, valued at
$2M
|
|
03/07/2018 |
4
| AGARWAL SUNIL (President of R & D) has filed a Form 4 on Juno Therapeutics, Inc.
Txns:
| Disposed/sold 84,549 shares
@ $0 Disposed/sold 29,135 shares
@ $0 Disposed/sold 35,893 shares
@ $0 Disposed/sold 313,797 options to buy
@ $24.01, valued at
$7.5M
|
|
03/06/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
03/06/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
03/06/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
03/06/2018 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
03/06/2018 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
03/06/2018 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta... |
03/06/2018 |
3
| CELGENE CORP /DE/ (10% Owner) has filed a Form 3 on Juno Therapeutics, Inc. |
03/05/2018 |
SC 13E3/A
| Form SC 13E3/A - Going private transaction by certain issuers: [Amend] |
03/05/2018 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
03/05/2018 |
SC 13D/A
| CELGENE CORP reports a 85.4% stake in JUNO THERAPEUTICS, INC. |
03/05/2018 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
03/01/2018 |
4
| Harr Steve (CFO & Head, Corp. Development) has filed a Form 4 on Juno Therapeutics, Inc.
Txns:
| Granted 11,544 shares
@ $0 |
|
03/01/2018 |
10-K
| Annual Report for the period ended December 31, 2017 |
02/22/2018 |
SC 13D/A
| CELGENE CORP reports a 9.7% stake in JUNO THERAPEUTICS, INC. |
02/22/2018 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
|
|
|